Dynavax Technologies Corporation
DVAXNASDAQHealthcare
$15.50
+$0.00(+0.00%)
Market Cap$1.8B
P/E Ratio—
52W High$15.73
52W Low$9.2
Dynavax Technologies Corporation (DVAX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · DVAX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.28B | $0.23B | $0.72B | $0.44B | $0.05B |
| Cost of Revenue | $0.05B | $0.05B | $0.26B | $0.17B | $0.01B |
| Gross Profit | $0.23B | $0.18B | $0.46B | $0.27B | $0.03B |
| Gross Margin %(computed) | 82.17% | 78.40% | 63.73% | 60.50% | 70.12% |
| Operating Expenses | |||||
| R&D Expenses | $0.06B | $0.05B | $0.05B | $0.03B | $0.03B |
| G&A Expenses | $0.17B | $0.15B | $0.13B | $0.10B | $0.08B |
| Total Operating Expenses | $0.23B | $0.22B | $0.18B | $0.13B | $0.11B |
| Operating Income | ($0.00B) | ($0.04B) | $0.28B | $0.13B | ($0.08B) |
| Operating Margin %(computed) | -1.49% | -15.94% | 39.23% | 30.60% | -161.59% |
| Interest Income | $0.04B | $0.03B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.01B | $0.01B | $0.01B | $0.01B | $0.02B |
| Income Before Tax | $0.03B | ($0.00B) | $0.29B | $0.08B | ($0.08B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | $0.03B | ($0.01B) | $0.29B | $0.08B | ($0.08B) |
| Net Margin %(computed) | 9.85% | -2.75% | 40.56% | 17.46% | -161.63% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.21 | $-0.05 | $2.32 | $0.62 | $-0.75 |
| Wtd Avg Shares | 0.13B | 0.13B | 0.13B | 0.12B | 0.10B |
| EBITDA | $0.05B | $0.01B | $0.31B | $0.10B | ($0.05B) |
| EBITDA Margin %(computed) | 16.48% | 4.16% | 42.58% | 21.79% | -100.63% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Dynavax Technologies Corporation data
About Dynavax Technologies Corporation (DVAX) Income Statement
Dynavax Technologies Corporation (DVAX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2024, DVAX reported revenue of $0.28B, gross profit of $0.23B (gross margin 82.17%), and net income of $0.03B — a net profit margin of 9.85%.
Frequently asked questions
DVAX · 4 questionsDynavax Technologies Corporation (DVAX) reported revenue of $0.28B for 2024, up 19.4% year-over-year.
DVAX revenueDVAX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08